{
    "item_type": "proposal",
    "title": "Valorisation of splice-switching oligonucleotides for lung cancer therapy",
    "descriptions": [
        "Abstract:\n\nThe \"Valorisation of Splice-Switching Oligonucleotides for Lung Cancer Therapy\" project is a groundbreaking initiative aimed at bridging the gap between basic molecular research and clinical applications in the fight against lung adenocarcinoma, a condition with high incidence, poor prognosis, and inadequate existing therapies. Leveraging the findings from the ERC-funded MASCP project, this proposal seeks to capitalize on splicing-modifying antisense oligonucleotides (SSOs) that have demonstrated the capability to modulate alternative splicing, repress cell growth in vitro, and inhibit tumor growth in vivo, when administered intranasally.\n\nOur experimental goal is to assess the therapeutic value of SSOs in patient-derived xenografts (PDX) in mice, a significant step towards validating their potential as a novel lung cancer treatment. The research will encompass testing SSOs in combination with chemotherapy, requiring optimization of dose and delivery route to ensure maximum efficacy and patient compatibility. Other valorisation activities include intellectual property protection and venture capital recruitment, with the ultimate business goal of establishing a spin-off company to facilitate the transition of this promising therapy from the laboratory to the market.\n\nThe project is supported by other healthcare innovation funds and has garnered interest from various stakeholders, indicating its potential for societal benefit. The ERC Proof of Concept (PoC) program is identified as a crucial funding need to advance these objectives. The anticipated outcome includes not only the advancement of a novel therapeutic strategy but also the enhancement of the European innovation landscape through the creation of intellectual property and new business opportunities in the healthcare sector. This proposal represents a strategic investment in the future of lung cancer therapy and the broader biotechnology industry."
    ],
    "origin": "LLM",
    "llm_engine": "gpt-4-1106-preview",
    "generation_prompt_uid": "df8dae7c8f95256e0d4eb44fe9fd7563",
    "generation_prompt_nickname": "from_json_details",
    "generation_prompt_text": "Write an abstract for a grant proposal based on the following details provided in JSON format. The JSON includes the title and key characteristics of the proposed project.\n\nPlease limit the response to 287 words or less.\n\n---\n\n**Description:**\n\n{'proposal_name': 'Valorisation of splice-switching oligonucleotides for lung cancer therapy', 'proposal_details': {'reagents': 'splicing-modifying antisense oligonucleotides', 'models': ['lung adenocarcinoma', 'patient-derived tumours in mice'], 'mechanism': 'alternative splicing', 'gene_regulation_impact': ['neurodegenerative disease', 'cancer'], 'project_reference': 'ERC-funded MASCP project', 'research_findings': {'antisense_oligonucleotides': {'modulates_splicing_of_cancer_gene': True, 'represses_cell_growth_in_vitro': True, 'inhibits_tumour_growth_in_mice': True, 'administration_route': 'intranasally'}}, 'experimental_goal': 'test therapeutic value in patient-derived xenografts in mice', 'combination_treatments_tested': ['chemotherapy'], 'optimization_required': ['dose', 'delivery route'], 'supporting_funds': 'other healthcare innovation funds', 'stakeholder_interest': True, 'funding_needs': ['ERC PoC program'], 'valorisation_activities': ['intellectual property protection', 'venture capital recruitment'], 'company_formation': 'spin-off company establishment', 'clinical_significance': {'lung_cancer': {'high_incidence': True, 'poor_prognosis': True, 'lack_of_efficient_therapies': True}}, 'descriptions': ['Translating fundamental knowledge on molecular mechanisms of gene regulation into applications for lung cancer therapy']}}\n\n**Description:**\n\n{'proposal_name': 'Valorisation of splice-switching oligonucleotides for lung cancer therapy', 'proposal_details': {'reagents': 'splicing-modifying antisense oligonucleotides', 'models': ['preclinical models of lung adenocarcinoma', 'patient-derived tumours in mice'], 'mechanism': 'alternative splicing', 'disease_link': 'cancer', 'previous_project': 'ERC-funded MASCP project', 'in_vitro_effects': ['repress cell growth'], 'in_vivo_effects': ['inhibit tumour growth'], 'administration_route': 'intranasally', 'experimental_goal': 'test therapeutic value in patient-derived xenografts in mice', 'combination_treatments': ['chemotherapy'], 'optimization_required': ['dose', 'delivery route'], 'supporting_funds': 'other healthcare innovation funds', 'stakeholder_interest': 'various', 'funding_needs': ['intellectual property protection', 'recruitment of venture capital'], 'business_goal': 'establish a spin-off company', 'clinical_relevance': ['high incidence', 'poor prognosis', 'lack of efficient therapies for lung cancer'], 'valorisation_potential': 'bridge the gap to market', 'societal_value': 'added value for society', 'descriptions': ['test the therapeutic potential of splicing-modifying antisense oligonucleotides']}}\n\n**Description:**\n\n{'proposal_name': 'Valorisation of splice-switching oligonucleotides for lung cancer therapy', 'proposal_details': {'reagents_type': 'splicing-modifying antisense oligonucleotides', 'condition_targeted': 'lung adenocarcinoma', 'models_used': ['preclinical models', 'patient-derived tumours in mice'], 'mechanism_of_action': 'modulate alternative splicing', 'related_project': 'ERC-funded MASCP project', 'in_vitro_effects': 'repress cell growth', 'in_vivo_effects': 'inhibit tumour growth', 'administration_route': 'intranasal', 'experimental_goal': 'test therapeutic value in patient-derived xenografts in mice', 'combination_treatments': ['chemotherapy'], 'optimization_needed': ['dose', 'delivery route'], 'current_funding': 'other healthcare innovation funds', 'stakeholders_interests': True, 'ERC_PoC_program_importance': True, 'intended_outcome': ['intellectual property protection', 'venture capital recruitment', 'establishment of spin-off company'], 'disease_impact': {'incidence': 'high', 'prognosis': 'poor', 'current_therapies_efficiency': 'lacking'}, 'valorisation_potential': True, 'descriptions': ['This proposal aims to translate fundamental knowledge of gene regulation into therapeutic applications for lung cancer, with potential for market valorisation and societal benefit.']}}"
}